Jefferies Upgrades Bausch Health Companies to Buy, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst David Steinberg has upgraded Bausch Health Companies (NYSE:BHC) from Hold to Buy and raised the price target from $9 to $16.
September 20, 2023 | 9:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch Health Companies has been upgraded to Buy from Hold by Jefferies, with a raised price target of $16, up from $9.
The upgrade from Hold to Buy by Jefferies indicates a positive outlook for Bausch Health Companies. The raised price target from $9 to $16 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100